Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity

Targeting Hsp90 is an effective strategy for cancer therapy. TAS-116 has been approved for the treatment of gastrointestinal stromal tumors. Our previous studies identified a series of pyrazole derivatives as covalent Hsp90 inhibitors that allosterically disrupt the Hsp90-Cdc37 interaction. Here, th...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Zi-Wen Feng (14608411) (author)
مؤلفون آخرون:	Li Li (14993) (author), Shi-Duo Zhang (14608414) (author), Ying-Ji Wang (21228156) (author), Jia-Yue Pei (21228159) (author), Nan-Nan Chen (15198729) (author), Bei-Duo Wu (15198735) (author), Qiu-Ling Zheng (13119805) (author), Qi-Dong You (294415) (author), Xiao-Ke Guo (459015) (author), Xiao-Li Xu (404540) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Cell Biology Pharmacology Biotechnology Sociology Cancer Chemical Sciences not elsewhere classified Information Systems not elsewhere classified previous studies identified novel mechanistic approach gastrointestinal stromal tumors collective findings underscore new covalent warhead 39 </ b covalent hsp90 inhibitors 50 </ sub covalent hsp90 50 μm therapeutic promise targeted disruption pyrazole derivatives pyrazole compounds knockout counterparts hsp90 regulators effective strategy cancer therapy allosterically disrupt (< b
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity

مواد مشابهة